TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer

MicroRNAs: Target Recognition and Regulatory Functions

Bartel, D. P. (2009) · Cell · doi:10.1016/j.cell.2009.01.002 · Cited by 20,068 · see citing works

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486 · see citing works

MicroRNA expression profiles classify human cancers

Lü, J., Getz, G. A., Miska, E. A., Alvarez-Saavedra, E., Lamb, J., Peck, D., Sweet-Cordero, A., Ebert, B. L., Mak, R. H., Ferrando, A. A., et al. (2005) · Nature · doi:10.1038/nature03702 · Cited by 9,497 · see citing works

<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368 · see citing works

<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496 · see citing works

EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib

Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338 · see citing works

Regulation of mRNA Translation and Stability by microRNAs

Fabian, M. R., Sonenberg, N., & Filipowicz, W. (2010) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060308-103103 · Cited by 3,214 · see citing works

Epidermal growth factor receptor mutations in lung cancer

Sharma, S. V., Bell, D. W., Settleman, J., & Haber, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2088 · Cited by 3,170 · see citing works

Unique microRNA molecular profiles in lung cancer diagnosis and prognosis

Yanaihara, N., Caplen, N., Bowman, E., Seike, M., Kumamoto, K., Yi, M., Stephens, R. M., Okamoto, A., Yokota, J., Tanaka, T., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.01.025 · Cited by 3,023 · see citing works

The NF- B Family of Transcription Factors and Its RegulationPreprint

Oeckinghaus, A., & Ghosh, S. (2009) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000034 · Cited by 2,850 · see citing works

NF-κB in cancer: from innocent bystander to major culprit

Karin, M., Cao, Y., Greten, F. R., & Li, Z. (2002) · Nature reviews. Cancer · doi:10.1038/nrc780 · Cited by 2,476 · see citing works

Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with <i>EGFR</i> -Mutant Lung Cancers

Yu, H. A., Arcila, M. E., Rekhtman, N., Sima, C. S., Zakowski, M. F., Pao, W., Kris, M. G., Miller, V. A., Ladanyi, M., & Riely, G. J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2246 · Cited by 2,454 · see citing works

Tumor necrosis factor signaling

Wajant, H., Pfizenmaier, K., & Scheurich, P. (2003) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401189 · Cited by 2,353 · see citing works

MicroRNA biogenesis pathways in cancer

Lin, S., & Gregory, R. I. (2015) · Nature reviews. Cancer · doi:10.1038/nrc3932 · Cited by 2,117 · see citing works

EGFR Antagonists in Cancer Treatment

Ciardiello, F., & Tortora, G. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0707704 · Cited by 2,063 · see citing works

Tumour necrosis factor and cancer

Balkwill, F. R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2628 · Cited by 1,925 · see citing works

Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome

Tsao, M., Sakurada, A., Cutz, J.-C., Zhu, C., Kamel‐Reid, S., Squire, J. A., Lorimer, I. A. J., Zhang, T., Liu, G., Daneshmand, M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050736 · Cited by 1,815 · see citing works

Addiction to Oncogenes--the Achilles Heal of Cancer

Weinstein, I. (2002) · Science · doi:10.1126/science.1073096 · Cited by 1,753 · see citing works

Epidermal Growth Factor Receptor in Non–Small-Cell Lung Carcinomas: Correlation Between Gene Copy Number and Protein Expression and Impact on Prognosis

Hirsch, F. R., Varella‐Garcia, M., Bunn, P. A., Maria, M. V. D., Veve, R., Bremnes, R. M., Barón, A. E., Zeng, C., & Franklin, W. A. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.069 · Cited by 1,476 · see citing works

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

Zhang, Z., Lee, J. C., Lin, L., Olivas, V., Au, V., LaFramboise, T., Abdel-Rahman, M., Wang, X., Levine, A. D., Rho, J. K., et al. (2012) · Nature Genetics · doi:10.1038/ng.2330 · Cited by 1,224 · see citing works

Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity

Yun, C.-H., Boggon, T. J., Li, Y., Woo, M. S., Greulich, H., Meyerson, M., & Eck, M. J. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.12.017 · Cited by 1,192 · see citing works

The quest to overcome resistance to EGFR-targeted therapies in cancer

Chong, C. R., & Janne, P. A. (2013) · Nature Medicine · doi:10.1038/nm.3388 · Cited by 1,055 · see citing works

Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation.

Moreira, A. L., Sampaio, E. P., Zmuidzinas, A., Frindt, P., Smith, K. A., & Kaplan, G. (1993) · The Journal of Experimental Medicine · doi:10.1084/jem.177.6.1675 · Cited by 1,041 · see citing works

Regulation of tumour necrosis factor signalling: live or let die

Brenner, D., Blaser, H., & Mak, T. W. (2015) · Nature Reviews Immunology · doi:10.1038/nri3834 · Cited by 998 · see citing works

Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition

Hata, A. N., Niederst, M. J., Archibald, H. L., Gomez-Caraballo, M., Siddiqui, F. M., Mulvey, H. E., Maruvka, Y. E., Ji, F., Bhang, H.-E. C., Krishnamurthy Radhakrishna, V., et al. (2016) · Nature Medicine · doi:10.1038/nm.4040 · Cited by 985 · see citing works

Understanding and targeting resistance mechanisms in NSCLC

Rotow, J. K., & Bivona, T. G. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2017.84 · Cited by 978 · see citing works

The BATTLE Trial: Personalizing Therapy for Lung Cancer

Kim, E. S., Herbst, R. S., Wistuba, I. I., Lee, J. J., Blumenschein, G. R., Tsao, A. S., Stewart, D. J., Hicks, M. E., Erasmus, J. J., Gupta, S. K., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8274.cd-10-0010 · Cited by 888 · see citing works

TNF and TNF-receptors: From mediators of cell death and inflammation to therapeutic giants – past, present and future

Sedger, L. M., & McDermott, M. (2014) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2014.07.016 · Cited by 774 · see citing works

Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR Mutants

Greulich, H., Chen, T.-H., Feng, W., Jänne, P. A., Alvarez, J. V., Zappaterra, M., Bulmer, S. E., Frank, D. A., Hahn, W. C., Sellers, W. R., et al. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020313 · Cited by 677 · see citing works

Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells

Lee, H.-J., Zhuang, G., Cao, Y., Du, P., Kim, H.-J., & Settleman, J. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.05.019 · Cited by 555 · see citing works

Signaling networks assembled by oncogenic EGFR and c-Met

Guo, A., Villén, J., Kornhauser, J. M., Lee, K. A., Stokes, M. P., Rikova, K., Possemato, A. P., Nardone, J., Innocenti, G., Wetzel, R. K., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707270105 · Cited by 502 · see citing works

MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers

Seike, M., Goto, A., Okano, T., Bowman, E. D., Schetter, A. J., Horikawa, I., Mathe, E. A., Jen, J., Yang, P., Sugimura, H., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905234106 · Cited by 500 · see citing works

Conformational Coupling across the Plasma Membrane in Activation of the EGF Receptor

Endres, N., Das, R., Smith, A. W., Arkhipov, A. S., Kovács, E., Huang, Y., Pelton, J. G., Shan, Y., Shaw, D. E., Wemmer, D. E., et al. (2013) · Cell · doi:10.1016/j.cell.2012.12.032 · Cited by 493 · see citing works

Lung adenocarcinomas induced in mice by mutant EGF receptors foundin human lung cancers respondto a tyrosine kinase inhibitor orto down-regulation of the receptors

Politi, K., Zakowski, M. F., Fan, P.-D., Schonfeld, E. A., Pao, W., & Varmus, H. E. (2006) · Genes &amp; Development · doi:10.1101/gad.1417406 · Cited by 478 · see citing works

Inhibition of NF-κB Activity by Thalidomide through Suppression of IκB Kinase Activity

Keifer, J. A., D, D. C. G., Ashburner, B. P., & Baldwin, A. S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100938200 · Cited by 477 · see citing works

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor–Resistant Disease

Ohashi, K., Maruvka, Y. E., Michor, F., & Pao, W. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.3912 · Cited by 467 · see citing works

TNF: A master switch for inflammation to cancer

Sethi, G. (2008) · Frontiers in Bioscience · doi:10.2741/3066 · Cited by 458 · see citing works

Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers

Gullick, W. J. (1991) · British Medical Bulletin · doi:10.1093/oxfordjournals.bmb.a072464 · Cited by 449 · see citing works

TNF receptor 2 pathway: drug target for autoimmune diseases

Faustman, D., & Davis, M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3030 · Cited by 446 · see citing works

FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR

Bivona, T. G., Hieronymus, H., Parker, J., Chang, K., Taron, M., Rosell, R., Moonsamy, P., Dahlman, K., Miller, V. A., Costa, C., et al. (2011) · Nature · doi:10.1038/nature09870 · Cited by 396 · see citing works

Engulfment of Apoptotic Cells by Macrophages: A Role of MicroRNA-21 in the Resolution of Wound Inflammation

Das, A., Ganesh, K., Khanna, S., Sen, C. K., & Roy, S. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1300613 · Cited by 320 · see citing works

Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC

CHAIB-OUKADOUR, I., Karachaliou, N., Pilotto, S., Servat, J. C., Cai, X., Li, X., Drozdowskyj, A., Codony, C., Yang, J. E., Hu, C., et al. (2017) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djx014 · Cited by 210 · see citing works

NF-κB-Activating Complex Engaged in Response to EGFR Oncogene Inhibition Drives Tumor Cell Survival and Residual Disease in Lung Cancer

Blakely, C. M., Pazarentzos, E., Olivas, V., Asthana, S., Yan, J. J., Tan, I., Hrustanovic, G., Chan, E., Lin, L., Neel, D. S., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.03.012 · Cited by 204 · see citing works

Ligand-Independent EGFR Signaling

Guo, G., Gong, K., Wohlfeld, B., Hatanpaa, K. J., Zhao, D., & Habib, A. A. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0989 · Cited by 198 · see citing works

Epidermal Growth Factor Receptor Mutants from Human Lung Cancers Exhibit Enhanced Catalytic Activity and Increased Sensitivity to Gefitinib

Mulloy, R., Ferrand, A., Kim, Y., Sordella, R., Bell, D. W., Haber, D. A., Anderson, K. S., & Settleman, J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4293 · Cited by 192 · see citing works

MicroRNA-21 Modulates the Levels of Reactive Oxygen Species by Targeting SOD3 and TNF α

Zhang, X., Ng, W. L., Wang, P., Tian, L., Werner, E., Wang, H., Doetsch, P. W., & Wang, Y. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0639 · Cited by 181 · see citing works

SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer

Ichihara, E., Westover, D., Meador, C. B., Yan, Y., Bauer, J. A., Lu, P., Ye, F., Kulick, A., de Stanchina, E., McEwen, R., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2300 · Cited by 150 · see citing works

Hippo pathway effector YAP inhibition restores the sensitivity of EGFR-TKI in lung adenocarcinoma having primary or acquired EGFR-TKI resistance

Lee, J. E., Park, H. S., Lee, D., Yoo, G., Kim, T., Jeon, H., Yeo, M., Lee, C. S., Moon, J. Y., Jung, S. S., et al. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.04.089 · Cited by 119 · see citing works

A TNF–JNK–Axl–ERK signaling axis mediates primary resistance to EGFR inhibition in glioblastoma

Guo, G., Gong, K., Ali, S., Ali, N., Shallwani, S., Hatanpaa, K. J., Pan, E., Mickey, B., Burma, S., Wang, D. H., et al. (2017) · Nature Neuroscience · doi:10.1038/nn.4584 · Cited by 114 · see citing works

Tyrosine Phosphoproteomics Identifies Both Codrivers and Cotargeting Strategies for T790M-Related EGFR-TKI Resistance in Non–Small Cell Lung Cancer

Yoshida, T., Zhang, G., Smith, M. A., Lopez, A. S., Bai, Y., Li, J., Fang, B., Koomen, J. M., Rawal, B., Fisher, K. J., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1559 · Cited by 106 · see citing works

Constitutive and ligand-induced EGFR signalling triggers distinct and mutually exclusive downstream signalling networks

Chakraborty, S., Li, L., Puliyappadamba, V. T., Guo, G., Hatanpaa, K. J., Mickey, B., Souza, R. F., Vo, P., Herz, J., Chen, M., et al. (2014) · Nature Communications · doi:10.1038/ncomms6811 · Cited by 99 · see citing works

MET-Independent Lung Cancer Cells Evading EGFR Kinase Inhibitors Are Therapeutically Susceptible to BH3 Mimetic Agents

Fan, W., Tang, Z., Yin, L., Morrison, B., Hafez-Khayyata, S., Fu, P., Huang, H., Bagai, R. K., Jiang, S., Kresak, A. M., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2668 · Cited by 83 · see citing works

Anti-inflammatory effects of miR-21 in the macrophage response to peritonitis

Barnett, R. E., Conklin, D. J., Ryan, L. E., Keskey, R. C., Ramjee, V., Sepulveda, E. A., Srivastava, S., Bhatnagar, A., & Cheadle, W. G. (2015) · Journal of Leukocyte Biology · doi:10.1189/jlb.4a1014-489r · Cited by 83 · see citing works

Suppression of Lipopolysaccharide-stimulated Tumor Necrosis Factor-α Production by Adiponectin Is Mediated by Transcriptional and Post-transcriptional Mechanisms

Park, P., Huang, H., McMullen, M. R., Mandal, P., Sun, L., & Nagy, L. E. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m802787200 · Cited by 67 · see citing works

Co-expression of epidermal growth factor receptor and transforming growth factor-α is independent of ras mutations in lung adenocarcinoma

Hsieh, E., Shepherd, F. A., & Tsao, M. (2000) · Lung Cancer · doi:10.1016/s0169-5002(00)00116-1 · Cited by 67 · see citing works

A genetic interaction analysis identifies cancer drivers that modify EGFR dependency

Liao, S., Davoli, T., Leng, Y., Li, M. Z., Xu, Q., & Elledge, S. J. (2017) · Genes &amp; Development · doi:10.1101/gad.291948.116 · Cited by 67 · see citing works

TNF-α mRNA is negatively regulated by microRNA-181a-5p in maturation of dendritic cells induced by high mobility group box-1 protein

Zhu, J., Wang, F., Wang, H., Dong, N., Zhu, X., Wu, Y., Wang, Y.-T., & Yao, Y.-M. (2017) · Scientific Reports · doi:10.1038/s41598-017-12492-3 · Cited by 58 · see citing works

Context-dependent roles for lymphotoxin-β receptor signaling in cancer development.

Fernandes, M., Dejardin, E., & dos Santos, N. (2016) · Biochimica et Biophysica Acta · doi:10.1016/j.bbcan.2016.02.005 · Cited by 44 · see citing works

Lymphotoxin-β Interacts with Methylated EGFR to Mediate Acquired Resistance to Cetuximab in Head and Neck Cancer

Hsu, D. S., Hwang, W., Yuh, C., Chu, C.-H., Ho, Y.-H., Chen, P.-B., Lin, H.-S., Lin, H., Wu, S.-P., Lin, C.-Y., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1955 · Cited by 34 · see citing works

LTβR signalling preferentially accelerates oncogenic AKT-initiated liver tumours

Scarzello, A. J., Jiang, Q., Back, T., Dang, H., Hodge, D., Hanson, C. A., Subleski, J., Weiss, J. M., Stauffer, J., Chaisaingmongkol, J., et al. (2015) · Gut · doi:10.1136/gutjnl-2014-308810 · Cited by 24 · see citing works

EGFR mutations and molecularly targeted therapy: a new era in the treatment of lung cancer

Dowell, J. E., & Minna, J. D. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0476 · Cited by 22 · see citing works

Epidermal growth factor ligand/receptor loop and downstream signaling activation pattern in completely resected nonsmall cell lung cancer

Volante, M., Saviozzi, S., Rapa, I., Ceppi, P., Cappia, S., Calogero, R., Novello, S., Borasio, P., Papotti, M. G., & Scagliotti, G. V. (2007) · Cancer · doi:10.1002/cncr.22903 · Cited by 20 · see citing works

Helping EGFR inhibition to block cancer

Warta, R., & Herold‐Mende, C. C. (2017) · Nature Neuroscience · doi:10.1038/nn.4605 · Cited by 14 · see citing works

New insights into the genetic etiology of Alzheimer’s disease and related dementias

Bellenguez, C., Küçükali, F., Jansen, I. E., Kleineidam, L., Moreno-Grau, S., Amin, N., Naj, A. C., Campos-Martin, R., Grenier-Boley, B., Andrade, V., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01024-z · Cited by 2,498 · see citing works

Applications of patient-derived tumor xenograft models and tumor organoids

Yoshida, G. J. (2020) · Journal of Hematology &amp; Oncology · doi:10.1186/s13045-019-0829-z · Cited by 471 · see citing works

Mitochondrial adaptation in cancer drug resistance: prevalence, mechanisms, and management

Jin, P., Jiang, J., Zhou, L., Huang, Z., Nice, E. C., Huang, C., & Fu, L. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01313-4 · Cited by 282 · see citing works

Autophagy and cancer drug resistance in dialogue: Pre-clinical and clinical evidence

Qin, Y., Ashrafizadeh, M., Mongiardini, V., Grimaldi, B., Crea, F., Rietdorf, K., Győrffy, B., Klionsky, D. J., Ren, J. T., Zhang, W., et al. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216307 · Cited by 214 · see citing works

CCL5 promotes breast cancer recurrence through macrophage recruitment in residual tumors

Walens, A., DiMarco, A. V., Lupo, R., Kroger, B. R., Damrauer, J. S., & Alvarez, J. V. (2019) · eLife · doi:10.7554/elife.43653 · Cited by 205 · see citing works

Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC: Dusk or Dawn?

Qiao, M., Jiang, T., Liu, X., Mao, S., Zhou, F., Li, X., Zhao, C., Chen, X., Su, C., Ren, S., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.04.003 · Cited by 186 · see citing works

Molecular and Clinical Features of EGFR-TKI-Associated Lung Injury

Ohmori, T., Yamaoka, T., Andō, K., Kusumoto, S., Kishino, Y., Manabe, R., & Sagara, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020792 · Cited by 112 · see citing works

Therapeutic Influence on Important Targets Associated with Chronic Inflammation and Oxidative Stress in Cancer Treatment

Неганова, М. Е., Liu, J., Aleksandrova, Y. R., Klochkov, S. G., & Fan, R. (2021) · Cancers · doi:10.3390/cancers13236062 · Cited by 110 · see citing works

A two-circular RNA signature as a noninvasive diagnostic biomarker for lung adenocarcinoma

Liu, X., Yang, Y., Liu, X., Zhang, M., Li, R., Yin, Y., & Qu, Y.-Q. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1800-z · Cited by 104 · see citing works

EGFR inhibition triggers an adaptive response by co-opting antiviral signaling pathways in lung cancer

Gong, K., Guo, G., Panchani, N., Bender, M. E., Gerber, D. E., Minna, J. D., Fattah, F., Gao, B., Peyton, M., Kernstine, K., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-0048-0 · Cited by 92 · see citing works

Tumor necrosis factor in lung cancer: Complex roles in biology and resistance to treatment

Gong, K., Guo, G., Beckley, N. A., Zhang, Y., Yang, X., Sharma, M., & Habib, A. A. (2020) · Neoplasia · doi:10.1016/j.neo.2020.12.006 · Cited by 86 · see citing works

Endothelial Pannexin 1 Channels Control Inflammation by Regulating Intracellular Calcium

Yang, Y., DeLalio, L. J., Best, A. K., Macal, E. H., Milstein, J. A., Donnelly, I., Miller, A. M., McBride, M., Shu, X. H., Koval, M. H., et al. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.1901089 · Cited by 78 · see citing works

Molecular Mechanisms of Resistance to Immunotherapy and Antiangiogenic Treatments in Clear Cell Renal Cell Carcinoma

Ballesteros, P. Á., Chamorro, J., Román, M. S., Pozas, J., Santos, V. G. D., Granados, Á. R., Grande, E., Alonso‐Gordoa, T., & Molina‐Cerrillo, J. (2021) · Cancers · doi:10.3390/cancers13235981 · Cited by 69 · see citing works

The MEK/ERK/miR-21 Signaling Is Critical in Osimertinib Resistance in EGFR-Mutant Non-Small Cell Lung Cancer Cells

Huang, W.-C., Yadav, V. K., Cheng, W.-H., Wang, C., Hsieh, M., Huang, T., Lin, S., Yeh, C., & Kuo, K.-T. (2021) · Cancers · doi:10.3390/cancers13236005 · Cited by 55 · see citing works

TP53 gain-of-function mutations promote osimertinib resistance via TNF-α–NF-κB signaling in EGFR-mutated lung cancer

Ibusuki, R., Iwama, E., Shimauchi, A., Tsutsumi, H., Yoneshima, Y., Tanaka, K., & Okamoto, I. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00557-2 · Cited by 47 · see citing works

Immune cell infiltration features and related marker genes in lung cancer based on single-cell RNA-seq

Zhong, R., Chen, D., Cao, S., Li, J., Han, B., & Zhong, H. (2020) · Clinical & Translational Oncology · doi:10.1007/s12094-020-02435-2 · Cited by 45 · see citing works

Understanding the Complexity of the Tumor Microenvironment in K-ras Mutant Lung Cancer: Finding an Alternative Path to Prevention and Treatment

Deng, S., Clowers, M. J., Velasco, W. V., Ramos-Castaneda, M. A., & Moghaddam, S. J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01556 · Cited by 44 · see citing works

Integrin-linked kinase (ILK) and src homology 2 domain-containing phosphatase 2 (SHP2): Novel targets in EGFR-mutation positive non-small cell lung cancer (NSCLC)

Karachaliou, N., Cardona, A. F., Bracht, J. W. P., Aldeguer, E., Drozdowskyj, A., Fernández-Bruno, M., CHAIB-OUKADOUR, I., Berenguer, J., Santarpía, M., Ito, M., et al. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.11.036 · Cited by 43 · see citing works

Drug resistance of targeted therapy for advanced non-small cell lung cancer harbored EGFR mutation: from mechanism analysis to clinical strategy

Zhao, Y., Wang, H., & He, C. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03828-8 · Cited by 43 · see citing works

Dihydroartemisinin overcomes the resistance to osimertinib in EGFR-mutant non-small-cell lung cancer

Cai, X., Jing, M., Sun, R., Wang, S., Molina‐Vila, M. Á., CHAIB-OUKADOUR, I., Rosell, R., & Cao, P. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105701 · Cited by 41 · see citing works

Endoplasmic reticulum stress induced autophagy in cancer and its potential interactions with apoptosis and ferroptosis

Liao, H., Liu, S., Ma, Q., Huang, H., Goel, A., Torabian, P., Mohan, C. D., & Duan, C. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2024.119869 · Cited by 39 · see citing works

A tyrosine kinase inhibitor-induced interferon response positively associates with clinical response in EGFR-mutant lung cancer

Gurule, N. J., McCoach, C. E., Hinz, T. K., Merrick, D. T., Bokhoven, A. V., Kim, J., Patil, T., Calhoun, J., Nemenoff, R. A., Tan, A. C., et al. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00181-4 · Cited by 39 · see citing works

TNF-α released from retinal Müller cells aggravates retinal pigment epithelium cell apoptosis by upregulating mitophagy during diabetic retinopathy

Liu, Y., Li, L., Pan, N., Gu, J., Qiu, Z., Cao, G., Dou, Y., Dong, L., Shuai, J., & Sang, A. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.05.027 · Cited by 39 · see citing works

Efficacy of EGFR plus TNF inhibition in a preclinical model of temozolomide-resistant glioblastoma

Guo, G., Gong, K., Puliyappadamba, V. T., Panchani, N., Pan, E., Mukherjee, B., Damanwalla, Z., Bharia, S., Hatanpaa, K. J., Gerber, D. E., et al. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz127 · Cited by 37 · see citing works

Cell-Intrinsic Mechanisms of Drug Tolerance to Systemic Therapies in Cancer

Léonce, C., Saintigny, P., & Ortiz‐Cuaran, S. (2021) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0038 · Cited by 37 · see citing works

EGFR-TNFR1 pathway in endothelial cell facilitates acute lung injury by NF-κB/MAPK-mediated inflammation and RIP3-dependent necroptosis

Zhang, H., Zhang, X., Ling, C., Liu, C., Hua, S., Xiong, Z., Zhao, H., Feng, Q., Feng, Z., Tang, J. Y., et al. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.109902 · Cited by 37 · see citing works

Targeting PKCι-PAK1 signaling pathways in EGFR and KRAS mutant adenocarcinoma and lung squamous cell carcinoma

Ito, M., Codony, C., Codony‐Servat, J., Lligé, D., CHAIB-OUKADOUR, I., Sun, X., Jing, M., Sun, R., Cai, X., Verlicchi, A., et al. (2019) · Cell Communication and Signaling · doi:10.1186/s12964-019-0446-z · Cited by 36 · see citing works

Dual Role of TNF and LTα in Carcinogenesis as Implicated by Studies in Mice

Gubernatorova, E. O., Polinova, A. I., Petropavlovskiy, M., Namakanova, O. A., Medvedovskaya, A. D., Zvartsev, R. V., Telegin, G. B., Drutskaya, M. S., & Nedospasov, S. A. (2021) · Cancers · doi:10.3390/cancers13081775 · Cited by 34 · see citing works

Mechanisms of EGFR-TKI-Induced Apoptosis and Strategies Targeting Apoptosis in EGFR-Mutated Non-Small Cell Lung Cancer

Nishihara, S., Yamaoka, T., Ishikawa, F., Higuchi, K., Hasebe, Y., Manabe, R., Kishino, Y., Kusumoto, S., Andō, K., Kuroda, Y., et al. (2022) · Genes · doi:10.3390/genes13122183 · Cited by 31 · see citing works

Changes of tumor microenvironment in non-small cell lung cancer after TKI treatments

Chen, S., Tang, J., Liu, F., Li, W., Yan, T., Shangguan, D., Yang, N., & Liao, D. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1094764 · Cited by 31 · see citing works

The roles of patient‐derived xenograft models and artificial intelligence toward precision medicine

Babu, J. V., ArulJothi, K. N., Mythili, V. M. R., Singh, S. K., Prasher, P., Gupta, G., Dua, K., Rakshith, H. S., Kaliappan, K., & Anand, K. (2024) · MedComm · doi:10.1002/mco2.745 · Cited by 28 · see citing works

Golden berry 4β-hydroxywithanolide E prevents tumor necrosis factor α-induced procoagulant activity with enhanced cytotoxicity against human lung cancer cells

Hsieh, K., Tsai, J., Lin, Y., Chang, F., Wang, H., & Wu, C. (2021) · Scientific Reports · doi:10.1038/s41598-021-84207-8 · Cited by 26 · see citing works

Combining Photodynamic Therapy and Targeted Drug Delivery Systems: Enhancing Mitochondrial Toxicity for Improved Cancer Outcomes

Merlin, J. P. J., Crous, A., & Abrahamse, H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910796 · Cited by 25 · see citing works

JK5G postbiotics attenuate immune-related adverse events in NSCLC patients by regulating gut microbiota: a randomized controlled trial in China

Chen, M., Ma, L., Yu, H., Huang, S., Zhang, J., Gong, J., Yang, L., Chen, L., Luo, H., Tian, L., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1155592 · Cited by 25 · see citing works

Heparin-based hydrogel scaffolding alters the transcriptomic profile and increases the chemoresistance of MDA-MB-231 triple-negative breast cancer cells

Menon, N., Dang, H. X., Datla, U. S., Moarefian, M., Lawrence, C. B., Maher, C. A., & Jones, C. N. (2020) · Biomaterials Science · doi:10.1039/c9bm01481k · Cited by 24 · see citing works

Integrated Network Pharmacology, Molecular Docking, Molecular Simulation, and In Vitro Validation Revealed the Bioactive Components in Soy-Fermented Food Products and the Underlying Mechanistic Pathways in Lung Cancer

Elkhalifa, A. E. O., Banu, H., Khan, M. I., & Ashraf, S. A. (2023) · Nutrients · doi:10.3390/nu15183949 · Cited by 23 · see citing works

Cyclosporine A sensitizes lung cancer cells to crizotinib through inhibition of the Ca2+/calcineurin/Erk pathway

Liu, Z., Jiang, L., Li, Y., Xie, B., Xie, J., Wang, Z., Zhou, X., Jiang, H., Fang, Y., Pan, H., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.03.019 · Cited by 22 · see citing works

TLR4 activation leads to anti-EGFR therapy resistance in head and neck squamous cell carcinoma.

Ju, H., Hu, Z., Lu, Y., Wu, Y., Zhang, L., Wei, D., Guo, W., Xia, W., Liu, S., Ren, G., et al. (2020) · PubMed Central · Cited by 22 · see citing works

Acquired Resistance in Lung Cancer

Tulpule, A., & Bivona, T. G. (2019) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030419-033502 · Cited by 21 · see citing works

Characteristics and molecular mechanism of drug-tolerant cells in cancer: a review

Liang, X.-W., Liu, B., Chen, J.-C., Cao, Z. W., Chu, F.-R., Xiong, L., Wang, S.-Z., & Wu, J. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1177466 · Cited by 20 · see citing works

Involvement of the TNF-α Pathway in TKI Resistance and Suggestion of TNFR1 as a Predictive Biomarker for TKI Responsiveness in Clear Cell Renal Cell Carcinoma

Hwang, H. S., Park, Y., Shin, S., Go, H., Park, J.-M., Yoon, S. Y., Lee, J., & Cho, Y. M. (2020) · Journal of Korean Medical Science · doi:10.3346/jkms.2020.35.e31 · Cited by 19 · see citing works

Targeting of drug-tolerant persister cells as an approach to counter drug resistance in non-small cell lung cancer

Izumi, M., Costa, D. B., & Kobayashi, S. S. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.107885 · Cited by 18 · see citing works

Novel Primary Human Cancer Stem-Like Cell Populations from Non-Small Cell Lung Cancer: Inhibition of Cell Survival by Targeting NF-κB and MYC Signaling

Windmöller, B. A., Beshay, M., Helweg, L. P., Flottmann, C., Beermann, M., Förster, C., Wilkens, L., Greiner, J. F. W., Kaltschmidt, C., & Kaltschmidt, B. (2021) · Cells · doi:10.3390/cells10051024 · Cited by 18 · see citing works

EGFR: New Insights on Its Activation and Mutation in Tumor and Tumor Immunotherapy

Gu, Y., He, H., Qiao, S., Shao, Y., Wang, L., Zhang, Z., Zhang, L., & Zhou, F. (2025) · Advanced Science · doi:10.1002/advs.202505785 · Cited by 17 · see citing works

Dual Targeting of EGFR and IGF1R in the TNFAIP8 Knockdown Non–Small Cell Lung Cancer Cells

Day, T. F., Kallakury, B., Ross, J. S., Voronel, O., Vaidya, S., Sheehan, C. E., & Kasid, U. N. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0731 · Cited by 17 · see citing works

A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer

Padda, S. K., Reckamp, K. L., Koczywas, M., Neal, J. W., Kawashima, J., Kong, S., Huang, D. B., Kowalski, M. M., & Wakelee, H. A. (2021) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-021-04369-0 · Cited by 17 · see citing works

IFITM3-MET interaction drives osimertinib resistance through AKT pathway activation in EGFR-mutant non–small cell lung cancer

Ibusuki, R., Iwama, E., Shimauchi, A., Kawano, H., Mizusaki, S., Nakamura, S., Miyazaki, Y., Inutsuka, Y., Hashisako, M., Harada, T., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02493-6 · Cited by 16 · see citing works

Single‐cell transcriptome analysis reveals cellular and molecular alterations in small cell lung cancer tumors following chemotherapy

Cheng, C., Zhu, G., Li, Y., Wang, H., Wang, S., Li, C., Feng, J., Wang, Z., & Li, W. (2023) · International Journal of Cancer · doi:10.1002/ijc.34629 · Cited by 16 · see citing works

Comprehensive targeting of resistance to inhibition of RTK signaling pathways by using glucocorticoids

Gong, K., Guo, G., Beckley, N. A., Yang, X., Zhang, Y., Gerber, D. E., Minna, J. D., Burma, S., Zhao, D., Akbay, E. A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27276-7 · Cited by 15 · see citing works

Phosphorylation by IKKβ Promotes the Degradation of HMGCL via NEDD4 in Lung Cancer

Zhong, C., Xiong, G., Yang, H., Du, X., Du, J., Yao, F., Fang, W., & Deng, Y. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.82015 · Cited by 14 · see citing works

Targeting mutant EGFR in non-small cell lung cancer in the context of cell adaptation and resistance

Roberts, S. K., Galgadas, I., Clarke, D. T., Zanetti-Domingues, L. C., Gervasio, F. L., & Martin-Fernandez, M. L. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104407 · Cited by 14 · see citing works

Unveiling the landscape of cytokine research in glioma immunotherapy: a scientometrics analysis

Zhang, H., Chen, Y., Jiang, X., Gu, Q., Yao, J., Wang, X., & Wu, J. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1333124 · Cited by 13 · see citing works

Potential Molecular Mechanism of TNF Superfamily-Related Genes in Glioblastoma Multiforme Based on Transcriptome and Epigenome

Xie, H., Yuan, C., Li, J., Li, Z., & Lu, W. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.576382 · Cited by 13 · see citing works

IRF1 as a potential biomarker in Mycobacterium tuberculosis infection

Wu, L., Cheng, Q., Wen, Z., Song, Y., Zhu, Y., & Wang, L. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16756 · Cited by 13 · see citing works

Emerging Role of Noncoding RNAs in EGFR TKI-Resistant Lung Cancer

Li, J., Li, P., Shao, J., Liang, S., Wan, Y., Zhang, Q., Li, C., Li, Y., & Wang, C. (2022) · Cancers · doi:10.3390/cancers14184423 · Cited by 13 · see citing works

Novel Therapeutic Anti-ADAM17 Antibody A9(B8) Enhances EGFR-TKI–Mediated Anticancer Activity in NSCLC

Yang, Z., Chan, K. I., Kwok, H. F., & Tam, K. Y. (2019) · Translational Oncology · doi:10.1016/j.tranon.2019.08.003 · Cited by 13 · see citing works

Metformin synergistically enhances the antitumor activity of the third‐generation EGFR‐TKI CO‐1686 in lung cancer cells through suppressing NF‐κB signaling

Pan, Y., Lin, C., Lu, C., Li, L., Wang, Y., Chen, H., & He, Y. (2018) · The Clinical Respiratory Journal · doi:10.1111/crj.12970 · Cited by 12 · see citing works

The functional significance of circRNA/miRNA/mRNA interactions as a regulatory network in lung cancer biology

Jia, S., Yu, L., Wang, L., & Peng, L. (2024) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2024.106548 · Cited by 11 · see citing works

Integrated circulating tumour DNA and cytokine analysis for therapy monitoring of ALK-rearranged lung adenocarcinoma

Angeles, A. K., Janke, F., Daum, A.-K., Reck, M., Schneider, M. A., Thomas, M., Christopoulos, P., & Sültmann, H. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02284-0 · Cited by 11 · see citing works

Immune cells in residual disease and recurrence

Ceyhan, Y., Garcia, N. M. G., & Alvarez, J. V. (2023) · Trends in cancer · doi:10.1016/j.trecan.2023.04.001 · Cited by 11 · see citing works

An overview of the crosstalk between YAP and cGAS-STING signaling in non-small cell lung cancer: it takes two to tango

Hao, F. (2022) · Clinical & Translational Oncology · doi:10.1007/s12094-022-02826-7 · Cited by 10 · see citing works

Chromosomal Instability Is Associated with cGAS–STING Activation in EGFR-TKI Refractory Non-Small-Cell Lung Cancer

Yonesaka, K., Kurosaki, T., Tanizaki, J., Kawakami, H., Tanaka, K., Maenishi, O., Takamura, S., Sakai, K., Chiba, Y., Teramura, T., et al. (2025) · Cells · doi:10.3390/cells14060447 · Cited by 9 · see citing works

Heterogeneity among tumors with acquired resistance to EGFR tyrosine kinase inhibitors harboring EGFR‐T790M mutation in non‐small cell lung cancer cells

Katayama, Y., Yamada, T., Tokuda, S., Okura, N., Nishioka, N., Morimoto, K., Tanimura, K., Morimoto, Y., Iwasaku, M., Horinaka, M., et al. (2022) · Cancer Medicine · doi:10.1002/cam4.4504 · Cited by 9 · see citing works

Association of Polymorphisms in Inflammation Genes With the Prognosis of Advanced Non-Small Cell Lung Cancer Patients Receiving Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

Zhang, X., Ye, T., Li, M., Yan, H., Lin, H. M., Lu, H., Qi, Z., Sheng, H., & Chun-ya, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.836117 · Cited by 7 · see citing works

Comparative study of TNF-α and vitamin D reveals a significant role of TNF-α in NSCLC in an ethnically conserved vitamin D deficient population

Bhat, I. A., Mir, I. R., Malik, G. H., Mir, J. I., Dar, T. A., Nisar, S., Naik, N. A., Sabah, Z. U., & Shah, Z. A. (2022) · Cytokine · doi:10.1016/j.cyto.2022.156039 · Cited by 7 · see citing works

The Identification of Key Gene Expression Signature and Biological Pathways in Metastatic Renal Cell Carcinoma

Bao, L., Zhao, Y., Liu, C., Cao, Q., Huang, Y., Chen, K., & Song, Z. (2020) · Journal of Cancer · doi:10.7150/jca.38379 · Cited by 7 · see citing works

Modulation of tumor inflammatory signaling and drug sensitivity by CMTM4

Xu, Y., Kang, K., Coakley, B. A., Eisenstein, S. G., Parveen, A., Mai, S., Wang, Y. S., Zheng, J., Boral, D., Mai, J., et al. (2025) · The EMBO Journal · doi:10.1038/s44318-024-00330-y · Cited by 6 · see citing works

It might be a dead end: immune checkpoint inhibitor therapy in EGFR-mutated NSCLC

Akao, K., Oya, Y., Sato, T., Ikeda, A., Horiguchi, T., Gotô, Y., Hashimoto, N., Kondo, M., & Imaizumi, K. (2024) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2024.00251 · Cited by 6 · see citing works

miRetrieve—an R package and web application for miRNA text mining

Friedrich, J., Hammes, H., & Krenning, G. (2021) · NAR Genomics and Bioinformatics · doi:10.1093/nargab/lqab117 · Cited by 5 · see citing works

Pulmonary toxicity in driver gene positive non-small cell lung cancer therapy

Zhao, Y., & Long, Y. (2022) · Current Medical Research and Opinion · doi:10.1080/03007995.2022.2085964 · Cited by 4 · see citing works

SOS1 inhibition suppresses the emergence of osimertinib resistance to generate a durable response in EGFR -mutant lung cancer

Daley, B. R., Theard, P. L., Hughes, J. M., Finniff, B. A., Hofmann, M. H., Kostyrko, K., Schenk, R. L., Vieira, H. M., Askew, J. W., Lewis, R. E., et al. (2025) · Science Signaling · doi:10.1126/scisignal.aea2788 · Cited by 4 · see citing works

Harnessing transcriptomics for discovery of natural products to overcome acquired cancer resistance

Yeo, H., Kim, S.-Y., & Park, S. (2025) · Archives of Pharmacal Research · doi:10.1007/s12272-025-01590-w · Cited by 4 · see citing works

Identification of Master Regulators Driving Disease Progression, Relapse, and Drug Resistance in Lung Adenocarcinoma

Xu, Q., Cha, Q., Qin, H., Liu, B., Wu, X., & Shi, J. (2022) · Frontiers in Bioinformatics · doi:10.3389/fbinf.2022.813960 · Cited by 4 · see citing works

EGFR inhibition down-regulates MGMT and enhances responsiveness to temozolomide in glioblastoma

Nayab, A., Mughal, N., Angez, M., Xing, S., Burma, A. M., Balla, H., Kizilbash, S. H., Yang, X., Maqbool, M. A., Arain, F. M., et al. (2026) · Science Translational Medicine · doi:10.1126/scitranslmed.adx8398 · Cited by 3 · see citing works

Mendelian Randomization Analysis of Non-small Cell Lung Cancer and Five Exposure Factors Based on Pathway Enrichment Analysis

Guo, Z., Zhang, J., Hu, Z., Wu, J., Zhou, W., Zhang, W., & Zhu, S. (2024) · Journal of Cancer · doi:10.7150/jca.98769 · Cited by 3 · see citing works

Cytokines as Potential Therapeutic Targets and their Role in the Diagnosis and Prediction of Cancers

Uchendu, I. K., Zhilenkova, A. V., Pirogova, Y. N., Basova, M., Bagmet, L. N., Kokhanovskaia, I. I., Tchawe, Y. S. N., Ikebunwa, O. A., & Sekacheva, M. I. (2023) · Current Pharmaceutical Design · doi:10.2174/0113816128268111231024054240 · Cited by 3 · see citing works

Uncovering the Anti-Lung-Cancer Mechanisms of the Herbal Drug FDY2004 by Network Pharmacology

Lee, H.-S., Lee, I.-H., Kang, K., Park, S., Kwon, T.-W., & Lee, D.-Y. (2021) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2021/6644018 · Cited by 3 · see citing works

Study of Therapeutic Mechanisms of Bupi Yichang Formula against Colon Cancer Based on Network Pharmacology, Machine Learning, and Experimental Verification

Du, J. (2023) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.2023051509 · Cited by 2 · see citing works

Integrative transcriptomic analysis identifies emetine as a promising candidate for overcoming acquired resistance to ALK inhibitors in lung cancer

Park, S., Haam, K., Heo, H., Kim, D., Kim, M., Jung, H., Cha, S., Kim, S., & Lee, H. (2024) · Molecular Oncology · doi:10.1002/1878-0261.13738 · Cited by 2 · see citing works

M2PP: a novel computational model for predicting drug-targeted pathogenic proteins

Wang, S., Li, J., & Wang, Y. (2022) · BMC Bioinformatics · doi:10.1186/s12859-021-04522-9 · Cited by 2 · see citing works

Inflammatory signaling in targeted therapy resistance: focus on EGFR-targeted treatment

Luo, Z., & Gong, K. (2024) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2024.0327 · Cited by 2 · see citing works

Spatial dynamics of the tumor microenvironment linked to emerging resistance in EGFR -mutated lung cancerPreprint

Nakamura, S., Shibahara, D., Tanaka, K., Kishikawa, Y., Hashisako, M., Nakatomi, K., Nakagaki, N., Kohno, M., Azuma, K., Ibusuki, R., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.10.637543 · Cited by 2 · see citing works

Epidermal Growth Factor Receptor in COPD and Lung Cancer: Is Inflammation the Culprit?

Agraval, H., Sharma, J. R., & Yadav, U. C. S. (2025) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-031-93894-8_3 · Cited by 1 · see citing works

Targeting Metabolic Vulnerabilities Reveals Hexokinase 2 as a Key Mediator of Resistance to Osimertinib in Non-Small Cell Lung Cancer Models

Guo, Y., Huang, D., Zhou, Y., Ran, M., Zhang, S., & Tam, K. Y. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00235 · Cited by 1 · see citing works

Effective Mixed-Type Tissue Crusher and Simultaneous Isolation of RNA, DNA, and Protein from Solid Tissues Using a TRIzol-Based Method

dos Santos, K. K., Daniel, I. W., Delabio, L. C., da Costa, M. A., Dutra, J. D. P., Ruginsk, B. E., Nardin, J. M., Campos, L. P., Rego, F. G. D. M., Picheth, G., et al. (2025) · J — Multidisciplinary Scientific Journal · doi:10.3390/j8010003 · Cited by 1 · see citing works

Composition and Bioactivity of a Modified Huang-Lian-Jie-Du Decoction

Lin, M., Chen, L.-G., Siao, Y.-Y., Lin, T.-H., Huang, I.-A., Liu, Y., & Huang, C.-C. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/2147923 · Cited by 1 · see citing works

Insights into EGFR Mutations and Oncogenic KRAS Mutations in Non-Small-Cell Lung Cancer

Rosell, R., Aguilar‐Hernández, A., & González‐Cao, M. (2023) · Cancers · doi:10.3390/cancers15092519 · Cited by 1 · see citing works

Transferrin receptor-based circulating tumor cell enrichment provides a snapshot of the molecular landscape of solid tumors and correlates with clinical outcomesPreprint

Galletti, G., Halima, A., Gjyrezi, A., Zhang, J., Zimmerman, B., Worroll, D., Kallergi, G., Bareja, R., Ocean, A. J., Saxena, A., et al. (2024) · medRxiv · doi:10.1101/2024.06.16.24309003 · Cited by 1 · see citing works

Do mRNA profiles of lung adenocarcinomas provide information that will help individual patients?

von Itzstein, M. S., Gerber, D. E., & Minna, J. D. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.103006

TNF-α suppresses drug resistance via NF-κB/PXR pathway in non-small cell lung cancerPreprint

Huang, W., Wang, P., Qi, S., Zhang, Y., Han, W., & Kong, Q. (2021) · Research Square · doi:10.21203/rs.3.rs-148624/v1

Location of EGFR exon 20 insertions matters

Cardona, A. F., González‐Cao, M., Arrieta, O. G., & Rosell, R. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.06.002

Therapy-Induced Dormancy and Residual Disease

DiMarco, A. V., Garcia, N. M. G., & Alvarez, J. V. (2022) · Springer eBooks · doi:10.1007/978-3-030-93084-4_10

Therapeutic Potential of Combining Receptor Tyrosine Kinase Inhibitor with Immune Checkpoint Blockade

D’Souza, A. D., & Ahn, R. (2025) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-031-93894-8_10

Tumor Microenvironment–Induced IFITM3 Activates MET–AKT Signaling to Drive Osimertinib Resistance in EGFR-Mutant NSCLC

Petrovic, M., & Jovanovic, A. (2023) · Archive of International Journal of Cancer and Allied Science · doi:10.51847/8a8ywycgnk

Phase Ib of repotrectinib plus osimertinib in patients with EGFR–mutated advanced non–small cell lung cancer

Aguilar, A., Cobo, M., Calles, A., Azkárate, A., Gonzalez-Cao, M., Molina‐Vila, M. A., & Rosell, R. (2026) · Lung Cancer · doi:10.1016/j.lungcan.2026.109461

Dissecting residual disease in spheroids reveals pan-cancer persistence signatures and a therapeutic window for oncolytic viruses

Fauveau, C., Lawendy, E., Deforges, J., Cochin, S., Moreau, B., Balloul, J., Erbs, P., Jain, S., & LAVERNY, G. (2026) · Molecular Therapy Oncology · doi:10.1016/j.omton.2026.201279

Interleukin‐1α‐Mediated Activation of TNF ‐α/ NF ‐ κB Signaling Confers Resistance to Osimertinib in EGFR ‐Mutant Non‐Small‐Cell Lung Cancer

Winardi, W., Mitsuishi, Y., Matsuda, H., Takahashi, F., Hayakawa, D., Kanamori, K., Nakamura, I., Wirawan, A., Hidayat, M., Wibowo, A., et al. (2026) · Thoracic Cancer · doi:10.1111/1759-7714.70360

Tumor necrosis factor in lung cancer: Complex roles in biology and resistance to treatment

Gong, K., Guo, G., Beckley, N. A., Zhang, Y., Yang, X., Sharma, M., & Habib, A. A. (2020) · Neoplasia · doi:10.1016/j.neo.2020.12.006 · Cited by 86 · see citing works

EGFR inhibition triggers an adaptive response by co-opting antiviral signaling pathways in lung cancer

Gong, K., Guo, G., Panchani, N., Bender, M. E., Gerber, D. E., Minna, J. D., Fattah, F., Gao, B., Peyton, M., Kernstine, K., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-0048-0 · Cited by 92 · see citing works

FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR

Bivona, T. G., Hieronymus, H., Parker, J., Chang, K., Taron, M., Rosell, R., Moonsamy, P., Dahlman, K., Miller, V. A., Costa, C., et al. (2011) · Nature · doi:10.1038/nature09870 · Cited by 396 · see citing works

Nimotuzumab enhances the sensitivity of non-small cell lung cancer cells to tumor necrosis factor-α by inhibiting the nuclear factor-кB signaling pathway

Zhu, J., Xin, Y., Liu, X., Wang, Y., & Liu, Y. (2018) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2018.5856 · Cited by 8 · see citing works

NF-κB-Activating Complex Engaged in Response to EGFR Oncogene Inhibition Drives Tumor Cell Survival and Residual Disease in Lung Cancer

Blakely, C. M., Pazarentzos, E., Olivas, V., Asthana, S., Yan, J. J., Tan, I., Hrustanovic, G., Chan, E., Lin, L., Neel, D. S., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.03.012 · Cited by 204 · see citing works